What are the details of your prescription?
Spiriva HandiHaler
Generic Name: Tiotropium Bromide Inhalation
Drug Category: Anticholinergic
Litigation Alert Level: High
This drug has been approved for use by males and females over the age of 18 years old for a maximum duration of 4 years.
| Approved Uses |
|
SPIRIVA HANDIHALER (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HANDIHALER is indicated to reduce exacerbations in COPD patients. Do not take more than one dose in 24 hours. SPIRIVA HANDIHALER is intended as a once-daily maintenance treatment for COPD and should not be used for relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. As a predominantly renally excreted drug, patients with moderate to severe renal impairment (creatinine clearance of <60 mL/min) treated with SPIRIVA HANDIHALER should be monitored closely for anticholinergic side effects. Inhaled medicines, including SPIRIVA HANDIHALER, may cause paradoxical bronchospasm. SPIRIVA HANDIHALER should be used with caution in patients with narrow-angle glaucoma. SPIRIVA HANDIHALER should be used with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue, or throat), rash, bronchospasm, anaphylaxis, or itching, may occur after administration of SPIRIVA HANDIHALER. Avoid co-administration of SPIRIVA HANDIHALER with other anticholinergic containing drugs as this may lead to an increase in anticholinergic adverse effects. The limited human data with SPIRIVA HANDIHALER use during pregnancy are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. Animal studies: increased post-implantation loss. Based on lactating rodent studies, tiotropium is excreted into breast milk. |
| Off-label Uses |
|
• Use in patients under the age of 18. GoToSource • Exceeding one dose in 24 hours. GoToSource |
| Adverse Events |
|
Use for more than 30 days increases risk of cardiovascular death, heart attack or stroke in patients with COPD. GoToSource Acute narrow-angle glaucoma. GoToSource COPD exacerbations. GoToSource Constipation, tachycardia (rapid heart rate), blurred vision, urinary retention and increased intraocular pressure. GoToSource |
| Litigation |
|
Lawsuits filed for heart attacks, strokes and death. |
The material contained in GoToPills is for informational purposes only and not intended to replace the judgment, evaluation and treatment of physicians, pharmacists and other healthcare providers. GoToPills does not provide medical advice, diagnoses or treatment. Always seek the advice of your physician or other qualified health provider regarding a medical condition or treatment.
